The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions
Falciparum; Malaria
Interventions
DRUG

Artemether-lumefantrine

Participants in the Artemether-Lumefantrine arm will be treated with standard doses of AL (Coartem, Novartis). Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered per manufacturer guidelines. All doses will be given under direct supervision with fatty food.

DRUG

Dihydroartemisinin-Piperaquine

Participants in the DHA-PPQ arm will be treated with standard doses of DHA-PPQ. Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau or Duocotecxin, Beijing Holley-Cotect Pharmaceutical Co) will be administered per manufacturer guidelines. All doses will be given under direct supervision on an empty stomach, as per manufacturer instructions.

Trial Locations (2)

Unknown

RECRUITING

Dr. Ambrosoli Memorial Hospital, Kalongo

RECRUITING

Patongo Health Facility IV, Patongo

All Listed Sponsors
collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

Radboud University Medical Center

OTHER

lead

Infectious Diseases Research Collaboration, Uganda

OTHER